- Conditions
- Herpes Zoster, Vaccine-Preventable Diseases
- Interventions
- Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901), Placebo
- Biological · Drug
- Lead sponsor
- Beijing Luzhu Biotechnology Co., Ltd.
- Other
- Eligibility
- 50 Years to 70 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Herpes Zoster
- Interventions
- Shingrix
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Inflammatory Bowel Diseases, IBD
- Interventions
- Adjuvanted Recombinant Zoster Vaccine (RZV)
- Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 19 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Baltimore, Maryland • New York, New York + 3 more
- Conditions
- Zoster, Zoster Varicella, Shingles, Chicken Pox
- Interventions
- Shingrix®
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Lymphoma
- Interventions
- AREXVY, ABRYSVO, PREVNAR 20, PNEUMOVAX 23, Heplisav -B, PREVNAR 13, Shingrix
- Drug · Biological
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2036
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Herpes Zoster, Allergy and Immunology, Corona Virus Infection
- Interventions
- SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline
- Biological · Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 65 Years to 100 Years
- Enrollment
- 217 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)
- Interventions
- Shingrix vaccine
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Interventions
- Zoster Vaccine Recombinant, Adjuvanted
- Biological
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
- Interventions
- FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Durham, North Carolina
- Conditions
- Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure, Kidney Failure, Chronic, Kidney Transplantation, Herpes Zoster (HZ)
- Interventions
- Shingrix
- Biological
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 1 more